Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2025-01-03T11:35:07.547Z Has data issue: false hasContentIssue false

2 - The basics of pharmacology and neurotransmission

Published online by Cambridge University Press:  18 December 2009

Donald E. Greydanus ,
Joseph L. Calles, Jr  and
Dilip R. Patel
By
Dilip R. Patel  and
Cynthia Feucht
Donald E. Greydanus
Affiliation:
Michigan State University
Joseph L. Calles, Jr
Affiliation:
Michigan State University
Dilip R. Patel
Affiliation:
Michigan State University
Dilip R. Patel
Affiliation:
Michigan State University
Cynthia Feucht
Affiliation:
Assistant Professor of Pharmacy Practice Ferris State University College of Pharmacy, Michigan State University/Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, USA
Get access

Summary

This chapter reviews basic concepts of pharmacology and neurotransmission applicable to psychotherapeutic agents used for the treatment of mental disorders of children and adolescents. An understanding of the basic principles of pharmacokinetics and pharmacodynamics of drugs is important in the appropriate therapeutic use of various drugs.

In simple terms the effects of the body on the drug once it has entered the body has been referred to as pharmacokinetics, and it aims to provide a quantitative assessment of the main processes involved in the biodisposition of the drug which include absorption, distribution, metabolism, and elimination. On the other hand, pharmacodynamics concerns itself with the effects of the drug on the body and the main processes involved are the action of the drug on specific sites, especially the receptors.

Pharmacokinetics

Absorption

A drug can be administered via various routes and the specific route chosen largely depends upon the urgency to achieve the desired effect in a given clinical circumstance. In our review of pediatric psychopharmacology we are mainly concerned with the oral route. Once ingested the drug is absorbed from the gastrointestinal tract. The extent of drug absorption is influenced by the surface area available for drug absorption, and local blood flow. In addition the absorption also depends on the characteristics of the drug itself such as its water solubility, dosage form, or concentration. Orally ingested drugs will undergo the first-pass effect before reaching the circulation (see below).

Type
Chapter
Information
Pediatric and Adolescent Psychopharmacology
A Practical Manual for Pediatricians
 , pp. 25 - 48
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Allison, C, Pratt, J A. 2003. Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol. Ther., 98(2):171–95.CrossRefGoogle ScholarPubMed
Bear, M F, Connors, B W, Paradiso, M A. 2007. Neuroscience: Exploring the Brain, 3rd edn.Baltimore: Lippincott Williams & Wilkins.Google Scholar
Beleboni, R O, Carolino, R O, Pizzo, A Bet al. 2004. Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships. Cell Mol. Neurobiol., 24(6):707–28.CrossRefGoogle ScholarPubMed
Berridge, C W, Waterhouse, B D. 2003. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev., 42(1):33–84.CrossRefGoogle ScholarPubMed
Braithwaite, S P, Paul, S, Nairn, A C, Lombroso, P J. 2006. Synaptic plasticity: one STEP at a time. Trends Neurosci., 29(8):452–8.CrossRefGoogle ScholarPubMed
Brambilla, P, Perez, J, Barale, F, Schettini, G, Soares, J C. 2003. GABAergic dysfunction in mood disorders. Mol. Psychiatry, 8(8):721–37.CrossRefGoogle ScholarPubMed
Buxton I L O. 2006. Pharmacokinetics and pharmacodynamics: The dynamics of drug absorption, distribution, action, and elimination. In Brunton, L, Parker, K, Lazo, J, Buxton, I, Blumenthal, D (Eds.) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edn.New York: McGraw Hill Medical.Google Scholar
Celine, F, Ouissame, M F, Nasser, H. 2006. Long-term adaptive changes induced by serotonergic antidepressant drugs. Expert Rev. Neurother., 6(2):235–45.Google Scholar
Centonze, D, Gubellini, P, Pisani, A, Bernardi, G, Calabresi, P. 2003. Dopamine, acetylcholine and nitric oxide systems interact to induce corticostriatal synaptic plasticity. Rev. Neurosci., 14(3):207–16.CrossRefGoogle ScholarPubMed
Chen, H S, Lipton, S A. 2006. The chemical biology of clinically tolerated NMDA receptor antagonists. J. Neurochem., 97(6):1611–26.CrossRefGoogle ScholarPubMed
Cooke, S F, Bliss, T V. 2006. Plasticity in the human central nervous system. Brain, 129 (Pt 7):1659–73.CrossRefGoogle ScholarPubMed
Damsa, C, Bumb, A, Bianchi-Demicheli, Fet al. 2004. “Dopamine-dependent” side effects of selective serotonin reuptake inhibitors: a clinical review. J. Clin. Psychiatry 65(8):1064–8.CrossRefGoogle ScholarPubMed
Dujardin, K, Laurent, B. 2003. Dysfunction of the human memory systems: role of the dopaminergic transmission. Curr. Opin. Neurol., 16 (Suppl. 2):S11–6.CrossRefGoogle ScholarPubMed
Ferraguti, F, Shigemoto, R. 2006. Metabotropic glutamate receptors. Cell Tissue Res., 326(2):483–504.CrossRefGoogle ScholarPubMed
Filip, M, Frankowska, M, Zaniewska, M, Golda, A, Przegalinski, E. 2005. The serotonergic system and its role in cocaine addiction. Pharmacol. Rep., 57(6):685–700.Google ScholarPubMed
Fritschy, J M, Brunig, I. 2003. Formation and plasticity of GABAergic synapses: physiological mechanisms and pathophysiological implications. Pharmacol. Ther., 98(3):299–323.CrossRefGoogle ScholarPubMed
Greene, J G. 2006. Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease. J. Physiol., 1; 575(Part 2):411–16.
Greenhill, L L, Tosyali, M C. 1998. Child and adolescent psychopharmacology: Important developmental issues. Pediatr. Clin. N. Am., 45(5):1021–36.Google Scholar
Hensler, J G. 2006. Serotonergic modulation of the limbic system. Neurosci. Biobehav. Rev., 30(2):203–14.CrossRefGoogle ScholarPubMed
Heresco-Levy, U. 2005. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg. Drugs, 10(4):827–44.CrossRefGoogle Scholar
Johnston, G A. 2005. GABA(A) receptor channel pharmacology. Curr. Pharm. Des., 11(15):1867–85.CrossRefGoogle ScholarPubMed
Kienast, T, Heinz, A. 2006. Dopamine and the diseased brain. CNS Neurol Disord Drug Targets, 5(1):109–31.CrossRefGoogle ScholarPubMed
Lee, F J, Wang, Y T, Liu, F. 2005. Direct receptor cross-talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine. J. Mol. Neurosci., 26(2–3):245–52.CrossRefGoogle ScholarPubMed
Lujan, R, Shigemoto, R, Lopez-Bendito, G. 2005. Glutamate and GABA receptor signaling in the developing brain. Neuroscience, 130(3):567–80.CrossRefGoogle ScholarPubMed
Majewska, A K, Sur, M. 2006. Plasticity and specificity of cortical processing networks. Trends Neurosci., 29(6):323–9.CrossRefGoogle ScholarPubMed
Mangina, C A, Sokolov, E N. 2006. Neuronal plasticity in memory and learning abilities: theoretical position and selective review. Int. J. Psychophysiol., 60(3):203–14.CrossRefGoogle ScholarPubMed
Marien, M R, Colpaert, F C, Rosenquist, A C. 2004. Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev., 45(1):38–78.CrossRefGoogle ScholarPubMed
Meredith, C W, Jaffe, C, Ang-Lee, K, Saxon, A J. 2005. Implications of chronic methamphetamine use: a literature review. Harv. Rev. Psychiatry, 13(3):141–54.CrossRefGoogle ScholarPubMed
Middlemiss, D N, Price, G W, Watson, J M. 2002. Serotonergic targets in depression. Curr. Opin. Pharmacol., 2(1):18–22.CrossRef
Mody, I, Pearce, R A. 2004. Diversity of inhibitory neurotransmission through GABA(A) receptors. Trends Neurosci., 27(9); 569–75.CrossRefGoogle ScholarPubMed
Pallas, S L, Wenner, P, Gonzalez-Islas, Cet al. 2006. Developmental plasticity of inhibitory circuitry. J. Neurosci., 26(41):10358–61.CrossRefGoogle ScholarPubMed
Pinheiro, P, Mulle, C. 2006. Kainate receptors. Cell Tissue Res., 326(2):457–82.CrossRefGoogle ScholarPubMed
Rollenhagen, A, Lubke, J H. 2006. The morphology of excitatory central synapses: from structure to function. Cell Tissue Res., 326(2):221–37.CrossRefGoogle ScholarPubMed
Sanger, D J. 2004. The search for novel antipsychotics: pharmacological and molecular targets. Expert Opin. Ther. Targets, 8(6):631–41.CrossRefGoogle ScholarPubMed
Scheffer, R F. 2006. Psychopharmacology: Clinical implications of brain neurochemistry. Pediatr. Clin. N. Am., 53:767–75.CrossRefGoogle ScholarPubMed
Schmitz, Y, Benoit-Marand, M, Gonon, F, Sulzer, D. 2003. Presynaptic regulation of dopaminergic neurotransmission. J. Neurochem., 87(2):273–89.CrossRefGoogle ScholarPubMed
Sem'yanov, A V. 2005. Diffusional extrasynaptic neurotransmission via glutamate and GABA. Neurosci. Behav. Physiol., 35(3):253–66.CrossRefGoogle ScholarPubMed
Sprengel, R. 2006. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res., 326(2):447–55.CrossRefGoogle ScholarPubMed
Stahl, D M. 2000. Essential Psychopharmacology: Neuroscientific Basis and Practical Application, 2nd edn. Cambridge: Cambridge University Press.Google Scholar
Szabadi, E. 2006. Drugs for sleep disorders: mechanisms for therapeutic prospects. Br. J. Clin. Pharmacol., 61(6):761–6.CrossRefGoogle ScholarPubMed
Wang, S J, Yang, T T. 2005. Role of central glutamatergic neurotransmission in the pathogenesis of psychiatric and behavioral disorders. Drug News Perspect., 18(9):561–6.CrossRefGoogle ScholarPubMed
Ziemann, U, Meintzschel, F, Korchounov, A, Ilic, T V. 2006. Pharmacological modulation of plasticity in the human motor cortex. Neurorehabil. Neural Repair, 20(2): 243–51.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×